In studies,<unk>  increased the rate of infections (27% of<unk>  treated patients, compared to 23% under placebo), including severe ones (0.6% versus 0.4% under placebo). Other common side effects included injection site pain (13–17% versus 3%), oropharyngeal pain (1%) and nausea (1–2%).
Ixekizumab
Caplacizumab
Satralizumab
Risankizumab
Brolucizumab
Bimekizumab
Tocilizumab
Etaracizumab